Prime medicine reports second quarter 2025 financial results and provides business updates

-- announced positive data from two patients in phase 1/2 clinical trial in chronic granulomatous disease (cgd), providing clinical proof-of-concept for prime editing; plan to have regulatory interactions based on current dataset -- -- completed follow-on offering, raising $144.2 million in gross proceeds and extending cash runway into 2027 --
PRME Ratings Summary
PRME Quant Ranking